Sunday, April 19, 2015
YOLO COUNTY NEWS
99 CENTS

Scientists find new target for lung cancer treatment

By
From page A5 | November 08, 2012 |

SACRAMENTO — A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy.

A series of experiments in mice with lung cancer showed that specific targeting of the protein with monoclonal antibodies reduced the size of tumors, lowered the occurrence of metastases and substantially lengthened survival time. The findings will be published in the November issue of Cancer Research.

“Lung cancer continues to be one of the biggest killers in the United States, and very few treatments directly target it,” said Joseph Tuscano, co-principal investigator of the study. “Our findings may ultimately lead to the identification of a novel and specific therapy for lung cancer.”

Lung cancer is the most common cause of death from cancer in both men and women in the United States. Despite new treatments, survival from non-small cell types of lung cancer — the most common form of the disease — averages less than one year.

The UC Davis investigation focused on CD22, a cell adhesion molecule, which is a protein on the surface of a cell. Its function is to bind with other cells or with the extracellular matrix, the non-cellular environment surrounding cells.

Although the researchers at first thought that CD22 was uniquely expressed on B lymphocytes, they discovered that it also appears on lung cancer cells but not on healthy cells in the lung.

The investigators found CD22 in seven of the eight cell lines evaluated, which included the major lung cancer subtypes of adenocarcinoma, squamous cell, bronchoalveolar and carcinoid. The authors examined publicly available databases and discovered that other lung cancer cell lines also expressed CD22.

“Our observation that CD22 is expressed on lung cancer cells is a very exciting discovery, especially since we already have developed a monoclonal antibody that targets this protein,” said Robert O’Donnell, co-principal investigator of the study.

“This could bring about a new treatment for a disease that badly needs a new therapeutic approach.”

Investigators next tested the effect of treating experimental mouse models of lung cancer with HB22.7: a monoclonal antibody they had earlier developed and used to target CD22 in successful treatments of non-Hodgkin’s lymphoma in mice. (HB22.7 is  currently being prepared for use in human patients in anticipation of clinical trials.)

They first implanted tumor cells in the lung. After the tumors reached a specific size, the mice were given four weekly treatments of either HB22.7 or a placebo.

Tumors in the mice treated with HB22.7 grew to only about half the size of those in the control mice.

HB22.7 also had positive results in a model that approximated lung-cancer metastasis, involving the ability of circulating cancer cells to implant themselves into an organ (in this case, the lung) and grow a tumor.

For these experiments, lung cancer cells were injected into the bloodstream of mice, followed by four weekly treatments of either HB22.7 or a placebo.

At the end of treatment, most of the lung tissue from the control group contained a great deal of tumor ― in one mouse the entire lung was nearly replaced with cancer. The treated mice had virtually no tumor growth in evidence, and only one had microscopic evidence of a single lung tumor.

Furthermore, mice treated with HB22.7 had significantly longer survival: more than 90 percent were still alive at the end of the 84-day trial, while most of the untreated mice had died by the 14th day, and all of them had died by day 40.

“The results of the metastasis experiments were really dramatic,” said Tuscano. “They indicate that CD22 may play a significant role in the development of lung-cancer metastasis.”

When HB22.7 was tested in a mouse model inoculated with a cell line found to be resistant to HB22.7 in cell culture, tumor growth was also significantly reduced compared to tumors in control mice. According to the authors, the reason for this is unclear, but they suspect that CD22 may have other immunological properties in a living animal not evident in tissue culture.

The research group is currently “humanizing” the monoclonal antibody HB22.7 in anticipation of clinical trials. This involves modifying the protein sequences to make the antibody ― which was derived from mice ― to be more similar to natural antibodies produced by humans.

Because they know that HB22.7 homes in on cancer cells, they also are exploring the use of HB22.7 as a vehicle to deliver drugs to lung cancer, which may make current drug therapy more effective.

— UC Davis Health System

Comments

comments

Dorsey Griffith

.

News

Aggie Pride on parade at UC Davis Picnic Day

By Wayne Tilcock | From Page: A1 | Gallery

 
City wants a study of sewer rates

By Dave Ryan | From Page: A1

Hard-of-hearing student needs community’s help

By Anne Ternus-Bellamy | From Page: A1 | Gallery

 
KDVS fund drive includes on-air pledging, plus parties and food

By Jeff Hudson | From Page: A1 | Gallery

 
 
Art helped sell California’s agriculture

By Special to The Enterprise | From Page: A3 | Gallery

 
Lawyers seek resolution to Davis molest case

By Lauren Keene | From Page: A4

Sign up now for Celebrate Davis!

By Enterprise staff | From Page: A4Comments are off for this post

 
Students, families can get after-hours Internet access

By Enterprise staff | From Page: A4

Garamendi hosts conference for women

By Special to The Enterprise | From Page: A5

 
‘Invaluable public servant’ retires after 20 years

By Tanya Perez | From Page: A5 | Gallery

Your brain’s aging and a new report urges ways to stay sharp

By The Associated Press | From Page: B5

 
Injury-proof yourself for effective exercise

By Special to The Enterprise | From Page: A6

Understanding risks can help women prevent leading health threats

By Special to The Enterprise | From Page: A7

 
Woodland bike rides set every Saturday

By Enterprise staff | From Page: A8

Get some advice at Connections Café

By Enterprise staff | From Page: A8

 
Eyewitness speaks about Israel’s election

By Special to The Enterprise | From Page: A8

Free gardening advice offered

By Enterprise staff | From Page: A8

 
Grad Night tickets on sale online

By Enterprise staff | From Page: A8

 
Schenker speaks about ‘Magical Mexico’

By Enterprise staff | From Page: A8

Yolo County DA honors crime victims at annual tribute

By Special to The Enterprise | From Page: A8

 
Holman offers Publishing 101 seminar

By Enterprise staff | From Page: A8

Radio-controlled airplanes will race April 25-26

By Enterprise staff | From Page: A8

 
Vote with your dollars at Davis Food Co-op

By Enterprise staff | From Page: A8

Join the 10,000-vegetable challenge!

By Enterprise staff | From Page: A9Comments are off for this post

 
NAMI group offers family support

By Enterprise staff | From Page: A9

Birding tour will benefit Putah Creek Council

By Special to The Enterprise | From Page: A10 | Gallery

 
Watershed Wonders activities return to Putah Creek

By Special to The Enterprise | From Page: A10

Yolo County Neighborhood Court seeks new volunteers

By Special to The Enterprise | From Page: A10

 
UCD looks at building a better brain as we age

By Enterprise staff | From Page: A11

‘Vault’ highlights ‘Kathak’

By Enterprise staff | From Page: A11

 
Two drought-preparedness water bills pass out of Senate committees

By Special to The Enterprise | From Page: A11

Picnic Day favorites: dogs, bikes science

By Wayne Tilcock | From Page: A13 | Gallery

 
Strike up the band, and the bubbles!

By Wayne Tilcock | From Page: A14 | Gallery

.

Forum

 
Ready for the parting glass

By Creators Syndicate | From Page: B5

 
Leash your dogs; it’s the law

By Letters to the Editor | From Page: B6

John Cole cartoon

By Debbie Davis | From Page: B6

 
Yolo Crisis Nursery still needs help

By Our View | From Page: B6

Drink up, kids, but make your choice a healthy one

By Special to The Enterprise | From Page: B6

 
Speak out

By Debbie Davis | From Page: B7

Let’s not turn our backs on the Earth

By Special to The Enterprise | From Page: B7

 
This Earth Day, make a pledge to cool your home

By Special to The Enterprise | From Page: B7

.

Sports

Fast Aggie start negated by 14-0 USC lacrosse run

By Bruce Gallaudet | From Page: B1 | Gallery

 
Stagnant second-half offense sinks Devil girls

By Thomas Oide | From Page: B1 | Gallery

Over the hump? DHS baseball team wins late

By Spencer Ault | From Page: B1 | Gallery

 
Lambdin, Marshall lead Aggies at Mt. SAC

By Enterprise staff | From Page: B1

Republic FC gets another win at Bonney

By Evan Ream | From Page: B2

 
UCD roundup: Aggies sweep a water polo double dip

By Enterprise staff | From Page: B2 | Gallery

Busy Clancy, Hall spark Devil tracksters at Mt. SAC

By Enterprise staff | From Page: B3 | Gallery

 
Former DHS star Drexel returns to create havoc for Aggies

By Bruce Gallaudet | From Page: B4 | Gallery

Pro baseball roundup: Oakland blanks Kansas City

By The Associated Press | From Page: B14

 
Sports briefs: Blue Devils split a pair of tennis matches

By Enterprise staff | From Page: B14 | Gallery

.

Features

.

Arts

.

Business

Marrone Bio Innovations strengthens its sales team

By Special to The Enterprise | From Page: A12

 
New phase opens at Brookfield Cottages

By Special to The Enterprise | From Page: A12

Tucos closes; new Japanese, pizza, subs debut

By Wendy Weitzel | From Page: A12 | Gallery

 
WISH grant funds available to eligible homebuyers

By Enterprise staff | From Page: A12

.

Obituaries

Alice Catherine Micheltorena

By Special to The Enterprise | From Page: A4

 
Jody Zewe

By Special to The Enterprise | From Page: A4

Herman Timm

By Special to The Enterprise | From Page: A4

 
Ruth Rodenbeck Stumpf

By Special to The Enterprise | From Page: A4

Robert Leigh Cordrey

By Special to The Enterprise | From Page: A4

 
.

Comics

Comics: Sunday, April 19, 2015

By Creator | From Page: B8